Study of BPR-6023021 for advanced cancer with bone spread
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug, BPR-6023021, for people whose cancer has spread to the bones and who have run out of standard options. The goal is to see if it can help control the cancer and ease symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must have spread to at least two spots in your bones, confirmed by scans.
- You must have tried standard treatments that didn't work, or you can't have them.
- You need to be well enough to take care of yourself (ECOG score 0 or 1).
- Your liver, kidneys, and blood counts must be adequate.
- If you can have children, you must use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SKB107, for people whose advanced cancer has spread to the bones and standard treatments no longer work. The goal is to see if SKB107 can help shrink or slow these bone tumors.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Hear when a new Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.